Addex Therapeutics ADXN
NASDAQ ADXN
$3.07 +0.09 (+3.02%)
At close: Oct 2, 2026 · 4:00 PM EDT

Addex Therapeutics (ADXN) Gains from Sales and Divestitures (2020 - 2021)

Updated

Addex Therapeutics (ADXN) reported Gains from Sales and Divestitures of -$137.73 for Q4 2021, compared with -$5,522 a year earlier.

Analysis

Addex Therapeutics (ADXN) Gains from Sales and Divestitures (2020 - 2021) Analysis & Trends

  • By year, Gains from Sales and Divestitures came in at -$5,522 in FY2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Addex Therapeutics 2.75 Mn 2.75 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 -137.73
Dec 31, 2020 -5,521.93
API Access

Addex Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=ADXN&period=max&api_key=YOUR_API_KEY